Upamostat Inhibitor

Name: Upamostat Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754081
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754081

Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Upamostat, Inhibitor

Full Product Name

Upamostat

Product Synonym Names

WX-671

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

629.81

Solubility

DMSO: 250mg/mL (396.95mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C32H47N5O6S

SMILES

O=C(N1CCN(C([C@@H](NS(=O)(C2=C(C(C)C)C=C(C(C)C)C=C2C(C)C)=O)CC3=CC=CC(C(NO)=N)=C3)=O)CC1)OCC

CAS Number

590368-25-5

Target & IC50

Serine protease

In Vitro

Upamostat is inhibitor of urokinase plasminogen activator (uPA). Upamostat is the oral pro-drug of the active metabolite WX-UK1, a novel inhibitor of uPA[1]. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, and plays a major role in tumor invasion and metastasis. Upamostat is the orally available amidoxime- (i.e. hydroxyamidine-) prodrug of the pharmacologically active form, WX-UK1[2].

Product Categories/Family for Upamostat, inhibitor

Proteases/Proteasome; Serine Protease

Product References and Citations for Upamostat, inhibitor

Heinemann V, et al. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
Heinemann V, et al. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
Froriep D, et al. Activation of the anti-cancer agent upamostat by the mARC enzyme system. Xenobiotica. 2013 Sep;43(9):780-4.
Froriep D, et al. Activation of the anti-cancer agent upamostat by the mARC enzyme system. Xenobiotica. 2013 Sep;43(9):780-4.
Park C, et al. HPLC-MS/MS analysis of mesupron and its application to a pharmacokinetic study in rats. J Pharm Biomed Anal. 2018 Feb 20;150:39-42.
Park C, et al. HPLC-MS/MS analysis of mesupron and its application to a pharmacokinetic study in rats. J Pharm Biomed Anal. 2018 Feb 20;150:39-42.

Other Notes

Small volumes of Upamostat, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Upamostat purchase

MBS5754081 is an inhibitor targeting Upamostat.